Fulgent Genetics, Inc.
FLGT
$18.50
$0.191.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -3.16% | 9.34% | 17.18% | 15.17% | 13.92% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.16% | 9.34% | 17.18% | 15.17% | 13.92% |
| Cost of Revenue | 10.04% | 14.40% | 7.97% | 6.36% | 6.46% |
| Gross Profit | -24.19% | 2.30% | 32.65% | 29.99% | 28.24% |
| SG&A Expenses | 10.51% | 49.65% | 16.30% | 29.27% | 10.76% |
| Depreciation & Amortization | 2.06% | 1.71% | 1.61% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.62% | 27.40% | 11.93% | 12.88% | 8.08% |
| Operating Income | -61.77% | -112.67% | 10.12% | -4.27% | 9.19% |
| Income Before Tax | -121.60% | -263.88% | 59.48% | -91.89% | 17.29% |
| Income Tax Expenses | -500.00% | -203.18% | 82.20% | -6.54% | 153.82% |
| Earnings from Continuing Operations | -112.40% | -282.07% | 53.55% | -111.84% | 14.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 21.41% | -23.18% | 373.91% | -21.32% | -3.91% |
| Net Income | -115.32% | -297.72% | 54.89% | -117.65% | 14.35% |
| EBIT | -61.77% | -112.67% | 10.12% | -4.27% | 9.19% |
| EBITDA | -87.53% | -183.64% | 16.55% | -7.10% | 8.32% |
| EPS Basic | -114.95% | -293.49% | 55.38% | -114.44% | 17.29% |
| Normalized Basic EPS | -103.19% | -252.98% | 15.55% | -3.27% | 20.72% |
| EPS Diluted | -114.95% | -292.59% | 55.38% | -114.00% | 17.29% |
| Normalized Diluted EPS | -103.19% | -252.98% | 15.55% | -3.27% | 20.72% |
| Average Basic Shares Outstanding | 0.16% | 1.07% | 1.09% | 1.48% | 3.57% |
| Average Diluted Shares Outstanding | 0.16% | 1.07% | 1.09% | 1.48% | 3.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |